Recent Updates from Supernus Pharmaceuticals
Piper Sandler has recently decided to downgrade Supernus Pharmaceuticals Inc (NASDAQ: SUPN). This decision is mainly due to growth in prescriptions for Qelbree, the company's leading ADHD medication, being slower than expected. The downgrade follows the unexpected lack of an increase in Qelbree prescriptions as students head back to school.
Qelbree's Performance Overview
Qelbree (viloxazine) is used to treat attention deficit hyperactivity disorder (ADHD) in both children and adults. During the second quarter, it reported a remarkable year-over-year sales growth of 92%, bringing in $59.4 million. Additionally, the total number of prescriptions hit 184,342, reflecting a 26% rise. However, despite these strong figures, the anticipated boost in prescriptions during the back-to-school season hasn't materialized, prompting a reassessment of future sales expectations.
Analyst Predictions on Sales Trends
The Piper analyst noted that management has recently shifted its focus toward improving Qelbree's financial aspects, including cutting back on copayment assistance. This indicates that the growth forecast for future prescription volumes might not be as robust as previously planned. While initial projections estimated peak sales nearing $500 million, the analyst now believes a target of around $400 million is more realistic.
Trends in Prescriptions
So far in 2023, Qelbree prescriptions have increased by 91% compared to the previous year. However, in the latest quarter, there was only a 1% rise in Q3 prescriptions, following a modest 4% increase in Q2. The overall ADHD medication market has also experienced challenges, showing a reported 2% decline in prescriptions.
FDA Developments and Future Outlook
Recently, the FDA accepted the resubmission of the new drug application (NDA) for Supernus’s apomorphine infusion device (SPN-830). This device aims to manage motor fluctuations in patients suffering from Parkinson’s disease. The user fee goal date (PDUFA date) for this application is set for February 2025. This comes after the FDA previously sent a Complete Response Letter in April, indicating the need for additional product quality information.
Supernus's Market Position
In light of the downgrade, Piper has changed its recommendation for Supernus Pharmaceuticals from Overweight to Neutral and lowered the target price to $36 from $41. This shift reflects the evolving market conditions and Qelbree's performance, which, despite these adjustments, continues to show growth.
Effects on Stock Performance
As per recent reports, SUPN stock has dropped 7.17%, settling at $31.09. Investors are keenly observing market trends and ongoing developments within the pharmaceutical sector, particularly regarding ADHD medications and associated products.
Frequently Asked Questions
What led to the downgrade of Supernus Pharmaceuticals?
The downgrade was mainly due to slower growth in Qelbree prescriptions than anticipated.
How did Qelbree perform in the latest quarter?
In the second quarter, Qelbree's sales increased by 92% compared to the same quarter last year, reaching a total of $59.4 million.
What are the new sales projections for Qelbree?
The analyst has adjusted the peak sales expectation for Qelbree to $400 million, down from the earlier estimate of $500 million.
Why is the FDA resubmission for SPN-830 important?
The FDA's acceptance of the NDA resubmission for SPN-830 is significant for treating motor fluctuations in Parkinson’s disease, with a review date scheduled for February 2025.
What has been the impact of the downgrade on stock performance?
After the downgrade, SUPN stock has fallen by 7.17%, reflecting ongoing concerns regarding prescription growth and the company's market position.
